EQT Life Sciences and CSL Forge a $2.2 Billion Partnership for Innovative Coagulation Treatment EQT Life Sciences and CSL have entered into a strategic collaboration with VarmX, highlighting a $2.2 billion agreement for developing an innovative coagulation agent.

EQT Life Sciences and CSL Forge a $2.2 Billion Partnership for Innovative Coagulation Treatment #None #CSL #VarmX #VMX-C001

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊

🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need

👉 buff.ly/aO4iHwV

#YsiosPortfolio #vc